CEO of the company Teva Pharmaceutical Industries Ltd (ADR)(NYSE:TEVA) said that the company will examine acquisition opportunities as it seeks to refocus on its generics business, expand in emerging markets and invest in the biosimilars sector. Teva Pharmaceutical Industries Ltd (ADR)(NYSE:TEVA) shares after opening at $50.91 moved to $50.94 on last trade day and at the end of the day closed at $49.86. Company price to sales ratio in past twelve months was calculated as 2.33 and price to cash ratio as 52.82. Teva Pharmaceutical Industries Ltd (ADR)(NYSE:TEVA) a positive weekly performance of 2.40%.
Zacks’ analyst wrote, “Bristol-Myers’ Squibb Co (NYSE:BMY) first quarter 2014 adjusted earnings of $0.46 per share beat the Zacks Consensus Estimate by 2 cents. Adjusted earnings were 12% above the year-ago figure driven by lower costs. Net sales (including the diabetes business) slipped 1% to $3.8 billion. Key oncology drugs performed very well in the quarter. Bristol-Myers has been trying to offset the declining sales of some of its important products by bringing in new products through in-licensing deals. We are positive on Bristol-Myers decision to sell its underperforming diabetes portfolio. ”Bristol-Myers Squibb Co (NYSE:BMY) shares advanced 0.57% in last trading session and ended the day on $49.80. BMY return on equity ratio is recorded as 19.40% and its return on assets is 8.00%. Bristol-Myers Squibb Co (NYSE:BMY) yearly performance is 28.12%.
Argus raised their price objective on shares of Merck & Co. (NYSE:MRK) from $62.00 to $66.00 in a research note issued on Wednesday, American Banking News reports. The firm currently has a “buy” rating on the stock. Argus’ price objective points to a potential upside of 10.70% from the company’s current price. Merck & Co., Inc.(NYSE:MRK) shares moved down -2.35% in last trading session and was closed at $58.22, while trading in range of $ 57.94 – 59.53. Merck & Co., Inc. (NYSE:MRK) year to date (YTD) performance is 17.24%.
Pfizer Inc. (NYSE:PFE) has already had its takeover overtures rebuffed three times by rival AstraZeneca Plc , but investors in the US drugmaker say it can tolerate a little more rejection before going hostile with the deal. AstraZeneca turned down a sweetened Pfizer cash and stock offer yesterday that amounted to £63 billion (RM347.2 billion), or about £50 per share, saying it substantially undervalued the British drugmaker. The raised offer followed unsolicited Pfizer approaches in late April and January. Pfizer Inc. (NYSE:PFE) company shares ended up $30.75. Pfizer Inc.(NYSE:PFE) distance from 50-day simple moving average (SMA50) is -2.60%. Analysts mean target price for the company is $34.05.